在实际临床实践中不同亚组的转移性HR+ HER2-乳腺癌患者使用药物阿来替尼克服激素耐药性的可能性

{"title":"在实际临床实践中不同亚组的转移性HR+ HER2-乳腺癌患者使用药物阿来替尼克服激素耐药性的可能性","authors":"R.V. Orlova Orlova, M. I. G. Gluzman, A.A. Vakhitova Vakhitova","doi":"10.18565/pharmateca.2023.11.66-71","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20153,"journal":{"name":"Pharmateca","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice\",\"authors\":\"R.V. Orlova Orlova, M. I. G. Gluzman, A.A. Vakhitova Vakhitova\",\"doi\":\"10.18565/pharmateca.2023.11.66-71\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20153,\"journal\":{\"name\":\"Pharmateca\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmateca\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18565/pharmateca.2023.11.66-71\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmateca","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18565/pharmateca.2023.11.66-71","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}